ofloxacin has been researched along with sparfloxacin in 175 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.57) | 18.7374 |
| 1990's | 100 (57.14) | 18.2507 |
| 2000's | 55 (31.43) | 29.6817 |
| 2010's | 19 (10.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, K; Egawa, H; Fujita, M; Kataoka, M; Matsumoto, J; Minamida, A; Miyamoto, T; Nishimura, Y; Okada, H; Shibamori, K | 1 |
| Sasabe, H; Sugiyama, Y; Tsuji, A | 1 |
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Cattoir, V; Mazel, D; Nordmann, P; Poirel, L; Soussy, CJ | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Arsène, S; Leclercq, R | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Cattoir, V; Espinal, P; Nordmann, P; Poirel, L; Silva-Sanchez, J | 1 |
| Baliani, A; Barrett, MP; Chollet, C; Gilbert, IH; Wong, PE | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Blango, MG; Mulvey, MA | 1 |
| Avdeef, A; Tam, KY | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Anderson, BE; Burda, WN; Cormier, R; Edlinger, J; Harrington, L; Kapolka, R; Kodigepalli, KM; Roma, G; Shaw, LN; Thomas, J; Turos, E | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Zhang, B | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Cobbs, CG; Smith, KR | 1 |
| Hammerschlag, MR; Hyman, CL; Roblin, PM | 1 |
| Bebear, C; Renaudin, H | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
| Citron, DM; Goldstein, EJ | 1 |
| Borner, E; Borner, K; Lode, H | 1 |
| Kumamoto, Y | 1 |
| Grosset, JH; Ji, B; Perani, EG; Petinon, C | 1 |
| Forstall, GJ; Knapp, CC; Washington, JA | 1 |
| Grosset, J; Ji, B; Truffot-Pernot, C | 1 |
| Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E | 1 |
| Cartwright, FD; Kenny, GE | 4 |
| Kamisaka, K; Kawahara, S; Kibata, M; Matsuyama, T; Mishima, Y; Nagare, J; Nakada, H; Tada, A; Yoshimoto, S | 1 |
| Goh, KS; Rastogi, N | 1 |
| Chin, NX; Gu, JW; Neu, HC; Yu, KW; Zhang, YX | 1 |
| Barry, AL; Fuchs, PC | 1 |
| Chaudhry, AZ; Knapp, CC; Sierra-Madero, J; Washington, JA | 1 |
| Kashimoto, S; Kojima, T; Kouno, K; Kurobe, N; Minami, A; Nakamura, S; Nakata, K; Ohue, T; Sakaguchi, Y; Yoshida, H | 1 |
| Iwamoto, Y; Miyake, Y; Okuda, K; Suginaka, H; Tsuruda, K | 1 |
| Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C | 1 |
| Citron, DM; Goldstein, EJ; Nesbit, CA | 1 |
| Jones, RN; Sutton, LD | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Kaatz, GW; Larsson, AJ; Moody, JA; Rotschafer, JC; Walker, KJ; Zabinski, RA | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Aoki, M; Goldstein, E; Kunii, O; Ono, Y | 1 |
| el-Kersh, TA; Ramadan, MA; Shibl, AM; Tawfik, AF | 1 |
| Cherubin, CE; Stratton, CW | 1 |
| Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA | 1 |
| Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R | 1 |
| Blanco, MT; Gómez-García, AC; Hurtado, C; Morán, FJ; Pérez-Giraldo, C; Rodríguez-Benito, A | 1 |
| Hammerschlag, MR; Montalban, G; Roblin, PM | 1 |
| Martínez-Martínez, L; Ortega, MC; Perea, EJ; Suárez, AI | 1 |
| Borobio, MV; Conejo, M; Perea, EJ; Ramirez, E; Suarez, AI | 1 |
| Banerjee, DK; McDermott-Lancaster, RD | 1 |
| Croizé, J; Le Noc, D; Le Noc, P | 1 |
| Ahlén, S; Malmborg, AS | 1 |
| Mitsuhashi, S; Yoshida, T | 1 |
| Chan, GP; Franzblau, SG; Parrilla, ML | 1 |
| Saito, H; Sato, K; Tomioka, H | 1 |
| Amsterdam, D; Beam, TR; Gorzynski, EA; Mandell, LA; Rotstein, C | 1 |
| Allen, SD; Baker, CN; Barry, AL; Fuchs, PC; Hardy, DJ; Jorgensen, JH; Murray, PR; Tenover, FC | 1 |
| Cormican, MG; Jones, RN | 1 |
| Berche, P; Gaillot, O | 1 |
| Verbist, L; Verhaegen, J | 1 |
| Hara, K; Ishida, K; Kaku, M; Koga, H; Kohno, S; Usui, T | 1 |
| Asaoka, T; Imamori, K; Maebashi, K; Matsuda, H; Matsumoto, M; Tahara, Y | 1 |
| Iakovlev, SV; Iakovlev, VP; Izotova, GN | 1 |
| Bobin, P; Grosset, J; Ji, B; Lienhardt, C; Traore, I | 1 |
| May, T; Portier, H; Proust, A | 1 |
| Chilima, BZ; Okazawa, Y; Tanno, K; Tosaka, M; Yamane, N | 1 |
| Hayakawa, I; Hohmura, M; Hoshino, K; Ishida, H; Kitamura, A; Nishino, T; Sato, K; Tanaka, M | 1 |
| Chambers, HF; Hackbarth, CJ; Kocagöz, T; Nikaido, H; Rosenberg, EY; Unsal, I | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Conejo, MC; García, I; Pascual, A; Perea, EJ; Salvador, J | 1 |
| Arvieux, C; Avril, JL; Cartier, F; Jacquelinet, C; Michelet, C; Vu, N | 1 |
| Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K | 1 |
| Bernard, FX; Bisch, D; Blanche, F; Cameron, B; Crouzet, J; Ferrero, L; Goniot, A; Lecoq, C; Manse, B; Maton, L; Ratet, N | 1 |
| Choi, EC; Choi, KH; Hong, JS; Kim, SK; Lee, DK; Yoon, SJ | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Ambrose, PG; Nightingale, CH; Owens, RC; Quintiliani, R | 1 |
| George, J; Morrissey, I | 1 |
| Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Kim, S; Kim, SJ | 1 |
| Adamantidis, MM; Bordet, R; Caron, JF; Dumotier, BM | 1 |
| Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL | 1 |
| Choi, EC; Choi, KH; Kim, BK; Kim, JH; Kim, JW; Lee, JH | 1 |
| Domon, H; Miyazaki, S; Yamaguchi, K; Yoshizumi, S | 1 |
| Brookings, E; Gray, B; Nix, S; Robinson, A; Swiatlo, E; Waites, K | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D | 1 |
| Baumann-Wilschke, I; Förster, C; Rücker, M; Shakibaei, M; Stahlmann, R; Vormann, J | 1 |
| Dorian, M; Grellet, J; Saux, MC | 1 |
| Dorr, MB; Ellison, W; Henry, D; Magner, DJ; Mansfield, DL; Sullivan, J; Talbot, GH | 1 |
| Bébéar, C; Bébéar, CM; Charron, A; de Barbeyrac, B; Dessus-Babus, S | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H | 1 |
| Hirayama, F; Ikeda, Y; Kawakita, T; Kuroda, T; Moriguchi, A; Sakurai, N; Sano, M; Uemori, S; Yamamoto, K | 1 |
| Biavasco, F; Mingoia, M; Montanari, MP; Prenna, M; Ripa, S; Varaldo, PE | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Dabernat, H | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Bébéar, C; Bébéar, CM; Leblanc, F; Renaudin, H; Schaeverbeke, T | 1 |
| Frémaux, A; Geslin, P; Sissia, G | 1 |
| Acar, JF; Goldstein, FW; Kitzis, MD; Miegi, M | 1 |
| Bryskier, A; Drugeon, HB; Juvin, ME | 1 |
| Gootz, TD; Haskell, SL; Kaczmarek, FS; Maurice, AE; Zaniewski, RP | 1 |
| Beyer, R; Cianciotto, NP; Noskin, GA; Pestova, E; Peterson, LR | 1 |
| Cartwright, FD; Huang, WM; Kenny, GE; Sjöström, KE; Young, PA | 1 |
| Bint, AJ; Legg, JM | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Hooper, DC | 2 |
| Hershberger, E; Rybak, MJ | 1 |
| Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
| Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP | 1 |
| Matsumoto, A; Matsushima, T; Miyashita, N | 1 |
| Bebear, C; Bebear, CM; Charron, A; Gruson, D; Lefrancois, M; Renaudin, H | 1 |
| Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
| Chiba, K; Hashimoto, K; Satoh, Y; Shiina, H; Sugiyama, A | 1 |
| Deb, DK; Srivastava, BS; Srivastava, KK; Srivastava, R | 1 |
| Ahr, HJ; Blotz, A; Blümel, J; Dubertret, L; Michel, L; Moysan, A; Vohr, HW | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Kashiwabara, Y; Matsuoka, M; Namisato, M | 1 |
| Lister, PD; Sanders, CC | 1 |
| Everett, D; Gillespie, SH; Morrissey, I | 1 |
| Kawahara, S; Nagare, H; Tada, A | 1 |
| Hovde, LB; Peterson, ML; Ross, GH; Rotschafer, JC; Wright, DH | 1 |
| Yagawa, K | 1 |
| Hu, D; Hu, P; Jiang, S; Jiang, Y; Li, S; Wang, Q; Zhu, L; Zou, Q | 1 |
| Hayakawa, H; Kawamura, Y; Miyazaki, M; Nagasawa, M; Nakamura, S; Nojima, Y | 1 |
| Hayakawa, H; Kawamura, Y; Takagi, K; Takano, YF; Tsuji, A | 1 |
| Cai, Y; Liang, D; Miao, J; Qiu, D; Wen, C; Xu, N | 1 |
| Chen, BY; Cheng, NN; Li, MH; Wang, YM; Zhang, LR | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Ono, C; Tanaka, M | 1 |
| Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM | 1 |
| Li, JL; Ma, XC; Tu, ZH; Xin, J; Zhang, T | 1 |
| Bao, L; Long, Y; Wu, YH; Xie, YX; Zeng, XW; Zhang, HD; Zhao, MC | 1 |
| Dong, C; Feng, YL | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Squire, SB; Vizel, AA; Ziganshina, LE | 1 |
| Gidoh, M | 1 |
| De Souza, MV; Junior, IN; Lourenço, MC | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Baeyens, WR; Fei, G; He, L; Huang, C; Ouyang, J; Wang, Y | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Anupama, M; Murthy, PB; Seiler, JP | 1 |
| Guo, J; Han, SN; Hu, ZS; Liu, JX; Shi, J; Zhang, LR; Zhang, XM; Zhang, Z; Zhao, ZZ | 1 |
| Kessissoglou, DP; Kljun, J; Polatoglou, E; Psomas, G; Tarushi, A; Turel, I | 1 |
| da Gama Jean Batista, D; da Silva, PB; de Nazaré C Soeiro, M; Gouvea, LR; Louro, SR; Martins, DA; Teixeira, LR | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Carneiro, ZA; de Albuquerque, S; de Oliveira, LP; de Souza, MVN; Guerra, W; Lima, MF; Lopes, CD; Paixão, DA; Pavan, FR; Pivatto, M; Ribeiro, CM; Teixeira, LR | 1 |
11 review(s) available for ofloxacin and sparfloxacin
| Article | Year |
|---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Ofloxacin; Pefloxacin; Quinolones; Renal Insufficiency | 1995 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
New generations of quinolones: with particular attention to levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones | 1997 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones; Sinusitis; Skin Diseases; Urinary Tract Infections | 1998 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sensitivity and Specificity; Sexually Transmitted Diseases; Urinary Tract Infections | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sexually Transmitted Diseases, Bacterial; Skin Diseases, Bacterial; Urinary Tract Infections | 2000 |
Latest industry information on the safety profile of levofloxacin in Japan.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Infective Agents; Central Nervous System; Chemical and Drug Induced Liver Injury; Dermatitis, Phototoxic; Drug Industry; Fluoroquinolones; Heart Diseases; Humans; Japan; Levofloxacin; Naphthyridines; Ofloxacin; Seizures; Substance Withdrawal Syndrome | 2001 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
8 trial(s) available for ofloxacin and sparfloxacin
| Article | Year |
|---|---|
Single-dose treatment of female acute uncomplicated cystitis.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Cefixime; Cefotaxime; Clinical Protocols; Colony Count, Microbial; Cystitis; Fluoroquinolones; Ofloxacin; Quinolones; Recurrence; Treatment Outcome; Urine | 1992 |
Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
Topics: Animals; Anti-Infective Agents; Cricetinae; Fluoroquinolones; Humans; Lung; Male; Mesocricetus; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Ofloxacin; Pneumonia, Mycoplasma; Quinolones | 1995 |
Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, Bacterial; Quinolones | 1996 |
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chlamydia Infections; Chlamydophila pneumoniae; Chronic Disease; Cough; Double-Blind Method; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Moraxella catarrhalis; Neisseriaceae Infections; Ofloxacin; Placebos; Pneumococcal Infections; Quinolones; Sputum; Staphylococcal Infections; Treatment Outcome | 1998 |
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Middle Aged; Ofloxacin; Quinolones; Recurrence; Treatment Outcome; Urinary Tract Infections | 1998 |
[A randomized controlled clinical study of sparfloxacin versus ofloxacin in the treatment of bacterial infections].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Ofloxacin | 1999 |
[Multicenter evaluation on the efficacy and safety of sparfloxacin in the treatment of acute bacterial infections].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Ofloxacin | 2002 |
A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Topics: Adult; Anti-Bacterial Agents; Asian People; China; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxacin; Female; Fluoroquinolones; Follow-Up Studies; Humans; Japan; Levofloxacin; Light; Male; Middle Aged; Ofloxacin; Scotland; Single-Blind Method; Skin Tests; Statistics, Nonparametric; White People | 2003 |
156 other study(ies) available for ofloxacin and sparfloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Molecular Conformation; Phenylbutyrates; Pseudomonas Infections; Rats; Streptococcal Infections; Structure-Activity Relationship; Theophylline; X-Ray Diffraction | 1990 |
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
Topics: Animals; Anti-Infective Agents; Bile; Biological Transport, Active; Fluoroquinolones; Glucuronates; Glutathione; Hyperbilirubinemia; Male; Piperazines; Quinolones; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley | 1998 |
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Computer Simulation; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Open Reading Frames; Plasmids; Polymerase Chain Reaction; Quinolones; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Vibrio | 2007 |
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; France; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Plasmids; Quinolones; Transformation, Genetic | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli.
Topics: Base Sequence; DNA Transposable Elements; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Quinolones | 2008 |
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif.
Topics: Animals; Eflornithine; Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Triazines; Trypanocidal Agents; Trypanosoma brucei brucei | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistance, Bacterial; Endosomes; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Recurrence; Urinary Bladder; Urinary Tract Infections; Urothelium | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Studies on the antimicrobial properties of N-acylated ciprofloxacins.
Topics: Acylation; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bartonella; Bartonella Infections; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2012 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones; Staphylococcus aureus; Staphylococcus epidermidis | 1992 |
In vitro activities of five quinolones against Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydophila pneumoniae; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1992 |
[In vitro activity of sparfloxacin against mycoplasmas].
Topics: Culture Media; Dose-Response Relationship, Drug; Doxycycline; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; In Vitro Techniques; Mycoplasma; Mycoplasma fermentans; Mycoplasma pneumoniae; Ofloxacin; Quinolones; Ureaplasma urealyticum | 1992 |
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae; Vancomycin; Virginiamycin | 1992 |
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones | 1992 |
Determination of sparfloxacin in serum and urine by high-performance liquid chromatography.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Ofloxacin; Quinolones; Spectrometry, Fluorescence | 1992 |
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Topics: Animals; Clarithromycin; Disease Models, Animal; Female; Fluoroquinolones; Foot; Hindlimb; Immunocompetence; Leprostatic Agents; Leprosy; Mice; Microbial Sensitivity Tests; Minocycline; Mycobacterium leprae; Ofloxacin; Quinolones; Rifampin | 1992 |
Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus | 1991 |
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Tuberculosis | 1991 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseases; Mice; Mice, Inbred Strains; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcus pneumoniae | 1991 |
Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
Topics: Anti-Infective Agents; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Ofloxacin; Quinolones; Tetracycline | 1991 |
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.
Topics: Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Quinolones; Tetracycline; Ureaplasma | 1991 |
[In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
Topics: Anti-Infective Agents; Antitubercular Agents; Fleroxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1991 |
In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin | 1991 |
In vitro activity of sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin | 1991 |
Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Staphylococcus; Staphylococcus aureus | 1991 |
Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Cell Adhesion; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin; Oxacillin; Plastics; Staphylococcus aureus; Staphylococcus epidermidis | 1990 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Lung Diseases; Mice; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Skin Diseases, Infectious; Urinary Tract Infections | 1989 |
In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria.
Topics: Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomonal Agents; Clindamycin; Erythromycin; Fluoroquinolones; Metronidazole; Microbial Sensitivity Tests; Minocycline; Miocamycin; Naphthyridines; Ofloxacin; Porphyromonas gingivalis; Prevotella intermedia; Quinolones; Tetracycline | 1995 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Isomerism; Isoniazid; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Splenomegaly; Survival Rate; Tuberculosis | 1995 |
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Wound Infection | 1995 |
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Topics: Ciprofloxacin; Diffusion; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Reproducibility of Results | 1995 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.
Topics: Anaerobiosis; Anti-Infective Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Staphylococcus aureus | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Effect of newer quinolones on the extra- and intra-cellular chemiluminescence response of human polymorphonuclear leucocytes.
Topics: Anti-Infective Agents; Ciprofloxacin; Extracellular Space; Fluoroquinolones; Humans; Luminescent Measurements; Neutrophils; Ofloxacin; Quinolones; Reactive Oxygen Species; Tetradecanoylphorbol Acetate; Zymosan | 1994 |
In vitro activity of subinhibitory concentrations of quinolones on urea-splitting bacteria: effect on urease activity and on cell surface hydrophobicity.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacteriaceae; Fluoroquinolones; Norfloxacin; Ofloxacin; Proteus; Providencia; Quinolones; Surface Properties; Urea; Urease | 1995 |
Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Listeriosis; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Stereoisomerism; Tuberculosis, Pulmonary | 1994 |
In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cricetinae; Fluoroquinolones; Humans; Levofloxacin; Lung; Mesocricetus; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Ofloxacin; Pneumonia, Mycoplasma; Quinolones | 1994 |
In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Staphylococcus epidermidis | 1994 |
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydophila pneumoniae; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones | 1994 |
Comparative in vitro activities of new quinolones against coryneform bacteria.
Topics: Anti-Infective Agents; Ciprofloxacin; Corynebacterium; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1994 |
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
Topics: Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1994 |
Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Fluoroquinolones; Leprosy; Mice; Mice, Nude; Microbial Sensitivity Tests; Mycobacterium leprae; Ofloxacin; Quinolones | 1993 |
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Topics: Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Ofloxacin; Piperazines; Quinolones; Ureaplasma urealyticum | 1993 |
[Compared antibacterial activity of a new fluoroquinolone, sparfloxacin (AT 4140, RP 64206) and four other fluoroquinolones against 332 strains of enteropathogen bacteria].
Topics: Anti-Infective Agents; Campylobacter jejuni; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Helicobacter pylori; Humans; In Vitro Techniques; Ofloxacin; Pefloxacin; Quinolones; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1993 |
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections | 1993 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.
Topics: Animals; Female; Fluoroquinolones; Leprosy; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Ofloxacin; Quinolones | 1993 |
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Topics: Animals; Anti-Infective Agents; Female; Fluoroquinolones; Gatifloxacin; Intracellular Fluid; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Piperazines; Quinolones | 1993 |
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1993 |
Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
Topics: Anti-Infective Agents; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Ofloxacin; Quality Control; Quinolones | 1993 |
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
Topics: Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1995 |
In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Topics: Adult; Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Ofloxacin; Otitis Media; Quinolones; Sinusitis | 1995 |
Comparative in vitro activity of BAY Y 3118 against selected species.
Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1995 |
In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone.
Topics: Anti-Infective Agents; Azepines; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Norfloxacin; Ofloxacin; Quinolones | 1995 |
Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; Foot; Mice; Mycobacterium leprae; Ofloxacin; Quinolones | 1996 |
[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Culture Media; Fluoroquinolones; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolones | 1996 |
Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Culture Media; Culture Media, Serum-Free; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Kinetics; Levofloxacin; Metals; Microbial Sensitivity Tests; Microscopy, Electron; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Urine | 1996 |
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Topics: Anti-Infective Agents; Antitubercular Agents; Base Sequence; Cell Wall; Cephaloridine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Permeability; Quinolones | 1996 |
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Topics: Anti-Infective Agents; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Naphthyridines; Ofloxacin; Quinolones; Ureaplasma urealyticum | 1996 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cisplatin; Doxorubicin; Fluoroquinolones; Humans; Levofloxacin; Neutrophils; Ofloxacin; Paclitaxel; Quinolones; Staphylococcus aureus | 1996 |
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Topics: Amoxicillin; Anti-Infective Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; HeLa Cells; Humans; Levofloxacin; Listeria monocytogenes; Ofloxacin; Quinolones; Rifampin; Sulfamethoxazole; Trimethoprim | 1997 |
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Topics: Animals; Anti-Infective Agents; Bone Marrow; Cells, Cultured; Ciprofloxacin; Cobalt Radioisotopes; Colony-Forming Units Assay; Culture Media, Conditioned; Fleroxacin; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Hemoglobins; Interleukin-3; Leukocyte Count; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Norfloxacin; Ofloxacin; Quinolones; Whole-Body Irradiation | 1997 |
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Escherichia coli; Fluoroquinolones; Novobiocin; Ofloxacin; Quinolones; Staphylococcus aureus; Substrate Specificity; Topoisomerase II Inhibitors | 1996 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Drug Eruptions; Fluoroquinolones; Gastrointestinal Diseases; Humans; Levofloxacin; Ofloxacin; Photosensitivity Disorders; Pneumonia; Quinolones | 1997 |
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Enterococcus faecalis; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1997 |
Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Reproducibility of Results | 1997 |
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Topics: Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Cats; Ciprofloxacin; Dogs; Fluoroquinolones; Haplorhini; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Swine; Wound Infection | 1997 |
The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae | 1997 |
Abnormal proteins enhance stress-induced cell death.
Topics: Anti-Infective Agents; Bacterial Proteins; Chaperonins; Enzyme Stability; Escherichia coli; Fluoroquinolones; Methionine-tRNA Ligase; Models, Molecular; Mutation; Ofloxacin; Peptide Fragments; Protein Conformation; Quinolones | 1998 |
Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers.
Topics: Action Potentials; Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Male; Ofloxacin; Purkinje Fibers; Quinolones; Rabbits; Stereoisomerism | 1998 |
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1998 |
In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Streptococcus pneumoniae | 1998 |
Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Topics: Anti-Infective Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1998 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic and Fetal Development; Extremities; Fleroxacin; Fluoroquinolones; Magnesium Deficiency; Mice; Microscopy, Electron; Ofloxacin; Pefloxacin; Quinolones | 1998 |
Uptake of fluoroquinolones in human monocytes isolated from peripheral blood.
Topics: Anti-Infective Agents; Cell Adhesion; Cell Separation; Ciprofloxacin; Flow Cytometry; Fluoroquinolones; Humans; Monocytes; Ofloxacin; Quinolones | 1998 |
Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
Topics: Amino Acid Sequence; Anti-Infective Agents; Base Sequence; Chlamydia trachomatis; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Molecular Sequence Data; Mutation; Ofloxacin; Quinolones | 1998 |
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Virginiamycin | 1998 |
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Stability; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Indicators and Reagents; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Ofloxacin; Quinolones; Solutions; Structure-Activity Relationship; Ultraviolet Rays | 1998 |
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1999 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Topics: Anti-Infective Agents; Ciprofloxacin; Doxycycline; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Piperazines; Ureaplasma urealyticum | 1999 |
In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Pefloxacin | 1999 |
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1999 |
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Topics: Adrenergic Uptake Inhibitors; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Drug Interactions; Drug Resistance, Microbial; Enzyme Inhibitors; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Reserpine; Staphylococcus aureus; Topoisomerase II Inhibitors | 1999 |
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Topics: Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Phenotype; Streptococcus pneumoniae; Transformation, Bacterial | 1999 |
Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.
Topics: Anti-Infective Agents; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Mycoplasma hominis; Ofloxacin; Point Mutation | 1999 |
Will pneumococci put quinolones in their place?
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Ofloxacin; Streptococcus pneumoniae | 1999 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Topics: Anti-Infective Agents; Catalysis; Ciprofloxacin; DNA; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Naphthyridines; Ofloxacin; Staphylococcus aureus; Topoisomerase II Inhibitors | 2000 |
In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Glycogen; Humans; Male; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Plasmids; Urethritis | 2000 |
In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycoplasma hominis; Naphthyridines; Ofloxacin; Ureaplasma urealyticum | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades.
Topics: Action Potentials; Animals; Anti-Infective Agents; Dogs; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart; Heart Block; Levofloxacin; Long QT Syndrome; Male; Models, Animal; Ofloxacin; Torsades de Pointes; Ventricular Dysfunction, Right | 2000 |
Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Cell Line; Coleoptera; Fluoroquinolones; Genes, Reporter; Luciferases; Luminescent Measurements; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium; Ofloxacin; Recombinant Proteins; Rifampin; Streptomycin; Transfection | 2000 |
Analyses of cutaneous fluoroquinolones photoreactivity using the integrated model for the differentiation of skin reactions.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Infective Agents; Biomarkers; Cell Membrane; Enoxacin; Female; Fluoroquinolones; Irritants; Mice; Models, Biological; Ofloxacin; Phenotype; Photosensitizing Agents; Quinolones; Skin | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Colony Count, Microbial; Dapsone; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Leprostatic Agents; Leprosy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mycobacterium leprae; Ofloxacin; Rifampin | 2000 |
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Quinolines | 2001 |
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Mycobacterium; Mycobacterium fortuitum; Mycobacterium kansasii; Mycobacterium tuberculosis; Ofloxacin | 2001 |
Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Bacteroides; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Time Factors | 2001 |
[Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Dermatitis, Phototoxic; Enoxacin; Female; Fluoroquinolones; Guinea Pigs; Nalidixic Acid; Ofloxacin; Oxazines; Quinolones; Rats; Rats, Sprague-Dawley; Ultraviolet Rays | 2002 |
Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats.
Topics: Animals; Anti-Infective Agents; Blood Proteins; Chromatography, High Pressure Liquid; Fluoroquinolones; Male; Metabolic Clearance Rate; Muscle, Smooth; Ofloxacin; Oxazines; Protein Binding; Rats; Rats, Wistar; Tissue Distribution | 2002 |
Inhibition by fluoroquinolones of K(+) currents in rat dissociated hippocampal neurons.
Topics: Animals; Dose-Response Relationship, Drug; Fleroxacin; Fluoroquinolones; Hippocampus; Levofloxacin; Membrane Potentials; Neurons; Ofloxacin; Patch-Clamp Techniques; Potassium Channels; Rats; Rats, Sprague-Dawley | 2003 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
Compare two methods of measuring DNA damage induced by photogenotoxicity of fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Comet Assay; Cricetinae; Cricetulus; DNA; DNA Damage; Fibroblasts; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Ultraviolet Rays | 2004 |
[Study on the gene mutation of quinolone-resistant Mycobacterium tuberculosis isolated from Sichuan Province].
Topics: Antibiotics, Antitubercular; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mutation; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single-Stranded Conformational; Quinolones | 2004 |
Simultaneous determination of trace of loxacin, ciprofloxacin, and sparfloxacin by micelle TLC-fluorimetry.
Topics: Anti-Bacterial Agents; Calibration; Chromatography, Thin Layer; Ciprofloxacin; Fluorometry; Fluoroquinolones; Micelles; Ofloxacin | 2004 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil.
Topics: AIDS-Related Opportunistic Infections; Brazil; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis | 2007 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Enhanced separation of seven quinolones by capillary electrophoresis with silica nanoparticles as additive.
Topics: Buffers; Electrophoresis, Capillary; Fleroxacin; Fluoroquinolones; Gatifloxacin; Nanoparticles; Ofloxacin; Oxazines; Quinolones; Silicon Dioxide | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods.
Topics: Anti-Infective Agents; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Ciprofloxacin; DNA Replication; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Lymphocytes; Ofloxacin | 2010 |
The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel.
Topics: Anti-Bacterial Agents; Cell Line; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gene Expression Regulation; Humans; Kidney; Levofloxacin; Ofloxacin; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Transport; Structure-Activity Relationship; Transfection | 2010 |
Interaction of Zn(II) with quinolone drugs: structure and biological evaluation.
Topics: Animals; Anti-Bacterial Agents; Cattle; Coordination Complexes; Crystallography, X-Ray; DNA; Fluoroquinolones; Humans; Levofloxacin; Models, Molecular; Ofloxacin; Protein Binding; Quinolones; Serum Albumin; Serum Albumin, Bovine; Zinc | 2011 |
Copper(II)-fluoroquinolone complexes with anti-Trypanosoma cruzi activity and DNA binding ability.
Topics: Animals; Cattle; Copper; DNA; Electron Spin Resonance Spectroscopy; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Ofloxacin; Organometallic Compounds; Spectrophotometry, Ultraviolet; Trypanocidal Agents; Trypanosoma cruzi | 2012 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Three new platinum complexes containing fluoroquinolones and DMSO: Cytotoxicity and evaluation against drug-resistant tuberculosis.
Topics: Cell Line, Tumor; Cell Survival; Ciprofloxacin; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor; Fluoroquinolones; Humans; MCF-7 Cells; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Multidrug-Resistant | 2018 |